Saxagliptin but Not Sitagliptin Inhibits CaMKII and PKC via DPP9 Inhibition in Cardiomyocytes

Some oral anti-hyperglycemic drugs, including gliptins that inhibit dipeptidyl peptidase 4 (DPP4), have been linked to the increased risk of heart failure (HF) in type-2 diabetic patients. While the cardiovascular safety trial, TECOS, revealed no link between sitagliptin and the risk of HF, a substa...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Physiol
Autors principals: Koyani, Chintan N., Trummer, Christopher, Shrestha, Niroj, Scheruebel, Susanne, Bourgeois, Benjamin, Plastira, Ioanna, Kickmaier, Sandra, Sourij, Harald, Rainer, Peter P., Madl, Tobias, Sattler, Wolfgang, Pelzmann, Brigitte, Malle, Ernst, von Lewinski, Dirk
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2018
Matèries:
Physiology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6246635/
https://ncbi.nlm.nih.gov/pubmed/30487758
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphys.2018.01622
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars